<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066339</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10012</org_study_id>
    <secondary_id>EORTC-10012</secondary_id>
    <secondary_id>IDBBC-10012</secondary_id>
    <nct_id>NCT00066339</nct_id>
  </id_info>
  <brief_title>Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy</brief_title>
  <official_title>An IDBBC Single Arm Phase II Trial Evaluating The Activity Of Iressa (ZD1839) In Metastatic Breast Cancer Patients Pretreated With An Antiestrogen And A Non-Steroidal Aromatase Inhibitor (Anastrozole Or Letrozole)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      tumor cell growth.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have&#xD;
      metastatic breast cancer that has not responded to antiestrogen and nonsteroidal aromatase&#xD;
      inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical benefit rate, defined as complete response, partial response, or&#xD;
           stable disease after at least 24 weeks, in patients receiving gefitinib for metastatic&#xD;
           breast cancer who progressed after prior antiestrogen and nonsteroidal aromatase&#xD;
           inhibitor therapy.&#xD;
&#xD;
        -  Determine the best overall response rate of patients treated with this drug.&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral gefitinib once daily. Treatment continues in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who go off study in the absence of disease progression are followed every 8 weeks&#xD;
      until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">44</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
          -  Radiological and/or clinical evidence of metastatic disease&#xD;
&#xD;
          -  Progressive disease after prior therapy with an antiestrogen (e.g., tamoxifen or&#xD;
             faslodex) and a nonsteroidal aromatase inhibitor (e.g., anastrozole or letrozole) in&#xD;
             the adjuvant and/or metastatic setting* NOTE: *Endocrine therapy must be the last&#xD;
             treatment before study entry&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
          -  No rapidly progressive visceral metastases&#xD;
&#xD;
          -  No uncontrolled CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor and/or progesterone receptor positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined as any of the following:&#xD;
&#xD;
               -  Natural menopause with at least 1 year since last menses&#xD;
&#xD;
               -  Radiation-induced oophorectomy with last menses more than 1 year ago&#xD;
&#xD;
               -  Chemotherapy-induced menopause with 1 year since last menses and serum&#xD;
                  follicle-stimulating hormone, luteinizing hormone, and plasma estradiol levels in&#xD;
                  the postmenopausal range&#xD;
&#xD;
               -  Surgical castration&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times ULN&#xD;
&#xD;
          -  No severe or uncontrolled hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  No severe or uncontrolled renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe or uncontrolled cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe or uncontrolled respiratory disease&#xD;
&#xD;
          -  No evidence of clinically active interstitial lung disease&#xD;
&#xD;
               -  Asymptomatic chronic stable radiographic changes allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix, contralateral breast cancer, or nonmelanoma skin cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
          -  No other severe or uncontrolled systemic disease&#xD;
&#xD;
          -  No known hypersensitivity to any excipients of gefitinib&#xD;
&#xD;
          -  No unresolved chronic toxicity greater than grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic breast cancer&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
          -  No concurrent radiotherapy to any metastatic site&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No surgery within 4 days after study drug administration&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior epidermal growth factor receptor inhibitor therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent use of any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum (St. John's Wort)&#xD;
&#xD;
          -  No concurrent systemic retinoids&#xD;
&#xD;
          -  No other concurrent investigational drugs or treatments&#xD;
&#xD;
          -  No other concurrent anticancer treatments&#xD;
&#xD;
          -  Concurrent bisphosphonates for the treatment and prevention of bony metastases are&#xD;
             allowed provided therapy was initiated before study enrollment* NOTE: *Bisphosphonates&#xD;
             may be initiated during study participation for the treatment of hypercalcemia only&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine J. Piccart-Gebhart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

